Cost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South Africa.
Jacqueline K MiotTrudy LeongSimbarashe TakuvaAndrew ParrishHalima DawoodPublished in: BMC health services research (2021)
The addition of flucytosine as induction therapy for the treatment of cryptococcal meningitis in patients infected with HIV is cost-effective when it is used as a 1-week AmBd/5FC regimen. Savings could be achieved with early discharge of patients as well as a reduction in the price of flucytosine.
Keyphrases
- hiv infected
- end stage renal disease
- ejection fraction
- newly diagnosed
- south africa
- antiretroviral therapy
- chronic kidney disease
- hiv positive
- prognostic factors
- peritoneal dialysis
- human immunodeficiency virus
- clinical trial
- hepatitis c virus
- mesenchymal stem cells
- cerebrospinal fluid
- combination therapy
- bone marrow
- replacement therapy
- study protocol
- men who have sex with men
- smoking cessation